Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News.

Check also Companies to Follow in 2022 and CMN Markets for the latest stock and market trends.

Always stay updated with the free CMN Newsletter.

Lempo Therapeutics

Main focus: Gene editing-based treatments for attenuating chronic disease

Company stage: Pre-clinical

Diseases (gene editing): Pulmonary Arterial Hypertension, PAH

Genome editing tool: CRISPR-Cas9

Funding stage: Private

Location: Binyamina, Israel



Lempo Therapeutics is an Israel-based, pre-clinical gene editing company, utilising CRISPR-Cas9 to edit stem-cells ex vivo, to inactivate disease causing myeloperoxidase (MPO) proteins in patients suffering from pulmonary arterial hypertension. Using CRISPR, Lempo edits CD34+ cells to knock out the MPO gene, after which the cells can be reinfused into patients.


HashtagLempo Therapeutics

Company: Lempo Therapeutics
Jobs, banner ads, webinars, sponsored content...
Search CRISPR Medicine